Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
Open accessThe DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC) is a heterogeneous disease with multiple underlying causative genetic mutations. Genetic mutations in the phosphatidylinositol-3 kinase (PI3K) and the mitogen activated protein kinase (MAPK) pathways are frequently implicated in CRC. Targeting the downstream substrate MEK in these mutated tumors stands out as a potential target in CRC. Several selective inhibitors of MEK have entered clinical trial evaluation; however, clinical activity with single MEK inhibitors has been rarely observed and acquired resistance seems to be inevitable. Amplification of the driving oncogene KRAS(13D), which increases signaling through the ERK1/2 pathway, upregulation of the noncanonical wingless/calcium signaling pathway (Wnt), and coexisting PIK3CA mutations have all been implicated with resistance against MEK inhibitor therapy in KRAS mutated CRC. The Wnt pathway and amplification of the oncogene have also been associated with resistance to MEK inhibitors in CRCs harboring BRAF mutations. Thus, dual targeted inhibition of MEK and PI3K pathway effectors (mTOR, PI3K, AKT, IGF-1R or PI3K/mTOR inhibitors) presents a potential strategy to overcome resistance to MEK inhibitor therapy. Many clinical trials are underway to evaluate multiple combinations of these pathway inhibitors in solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although BEZ235 showed satisfactory antitumor activity against various cancer types in a preclinical model, poor tolerability and high adverse events were observed in clinical trials38–41.”
From Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast to the MAPK pathway, the PI3K/AKT pathway primarily regulates cell survival, metabolism, growth, and drug resistance [10,11].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [11]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although BEZ235 showed satisfactory antitumor activity against various cancer types in a preclinical model, poor tolerability and high adverse events were observed in clinical trials38–41.”
From Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization (2025) · cites this paper as [40]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216 · cited 1×
“Class 1 PI3K family members that convert phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3) thereby activating AKT via two crucial phosphorylation events at threonine 308 catalyzed by phosphoinositide-dependent kinase-1 (PDK1) and at serine 473 catalyzed by mammalian target…”
BackgroundMammalian MAP kinase signalling cascades
Chang, L., & Karin, M. (2001) · Nature · doi:10.1038/35065000 · Cited by 5,111 · cited 1×
“Activated MEK phosphorylates its only substrate ERK1/2 leading to dimerization, nuclear translocation and induction of target genes [5,6].”
BackgroundmTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Molecular mechanisms of mTOR-mediated translational control
Ma, X. M., & Blenis, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2672 · Cited by 2,558 · cited 1×
“mTORC1 has been shown to regulate cell growth by controlling mRNA translation initiation and to regulate ribosome biogenesis, autophagy and lipid biosynthesis [34].”
BackgroundDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 1×
“Coexisting mutations of the PIK3CA, which occur in about 8%–9% of CRC cases [25,26], have also been implicated in the resistance of KRAS mutated CRC cells to MEK inhibition [27,28].”
BackgroundPI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845 · cited 1×
“Genetic anomalies of PI3K pathway components, such as PTEN loss, PI3K amplification/mutation, AKT mutation or RTK activation, result in activation of this pathway leading to tumorigensis [3].”
BackgroundBRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328 · cited 1×
“RAS and RAF gene mutations have been considered potential markers of sensitivity to MEK inhibition largely due to the constitutive activation of MEK seen in BRAF mutant cancer cells and to a lesser extent in KRAS mutant cells [17,18].”
BackgroundThe insulin-like growth factor system and cancer
LeRoith, D., & Roberts, C. T. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00159-9 · Cited by 1,124 · cited 1×
“Insulin-like growth factor-1 receptor (IGF-1R) is a key activator of these two pro-survival signaling pathways [1].”
BackgroundThe PTEN–PI3K pathway: of feedbacks and cross-talks
Carracedo, A., & Pandolfi, P. P. (2008) · Oncogene · doi:10.1038/onc.2008.247 · Cited by 878 · cited 1×
“mTOR inhibition has been correlated with activation of MAPK pathway through PI3K’s activation of RAS [42].”
BackgroundPhosphorylation of the MAP Kinase ERK2 Promotes Its Homodimerization and Nuclear Translocation
Khokhlatchev, A. V., Canagarajah, B., Wilsbacher, J., Robinson, M., Atkinson, M., Goldsmith, E., & Cobb, M. H. (1998) · Cell · doi:10.1016/s0092-8674(00)81189-7 · Cited by 677 · cited 1×
“Activated MEK phosphorylates its only substrate ERK1/2 leading to dimerization, nuclear translocation and induction of target genes [5,6].”
Background
Cited by
Items 101–127 of 127
Henrykowska, G., Bartusik-Aebisher, D., Dynarowicz, K., Ramesh, T. S., Smolak, B., & Aebisher, D. (2026) · Pharmaceuticals · doi:10.3390/ph19071041 · Cited by 1
“In contrast to the MAPK pathway, the PI3K/AKT pathway primarily regulates cell survival, metabolism, growth, and drug resistance [10,11].”
Pu, B.-P., Wang, P., Guo, K.-K., Liu, C., Chen, S.-R., Li, X., Chen, S., Zeng, X., & Gao, C. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i9.109378 · Cited by 1
“Studies have shown that rapamycin and its derivatives have achieved good therapeutic effects in combination therapy with other anticancer drugs, and have overcome drug resistance in tumors[77,78].”
The multifaceted roles of ZIC genes in cancer: from development regulators to cancer modulators
Hesham, D., & El‐Naggar, S. (2025) · Discover Oncology · doi:10.1007/s12672-025-03511-1 · Cited by 1
Rodriguez, V., Villani, A., Sénica, M., Panebianco, C., Pazienza, V., & Preto, A. (2026) · Cancers · doi:10.3390/cancers18030369 · Cited by 1
Kaladhar, D. S., & Tantravahi, S. (2021) · Springer eBooks · doi:10.1007/978-3-030-63369-1_12 · Cited by 1
Shifting KRAS hotspot mutations inhibition paradigm in colorectal cancerPreprint
Brás, A. R., Lopes, A., Mendes, N. M., Costa, P. J., Ferreira, A. I., Granja, S., da Silva, A. P. M., Tortosa, F., Baltazar, F., Gärtner, F., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.09.552513 · Cited by 1
The role of ERK5 signaling in colorectal cancer
(2016) · Cancer Cell & Microenvironment · doi:10.14800/ccm.1437
“skin rash, liver and gastrointestinal symptoms) have been frequently reported ([13]).”
BackgroundCiblage de la voie PI3K/mTOR dans les léiomyosarcomes : sensibilité et mécanismes de résistance
Fourneaux, B. (2017) · theses.fr (ABES) · doi:10.70675/3f0ab847z27b0z4e03zad9ez3cb6ed282770
The features of KRAS gene transcriptional activity and significance in colorectal cancer
Shyshkin, M. A., & Tumanskiy, V. A. (2019) · Reports of Vinnytsia National Medical University · doi:10.31393/reports-vnmedical-2019-23(1)-27
Henderson, R. (2019) · Research Portal (Queen's University Belfast)
Molecular Biomarkers for the Evaluation of Colorectal Cancer
Willis, J. E., Monzon, F. A., Clark, J. R., Lieu, C. H., Hamilton, S. R., Temple‐Smolkin, R., Allegra, C. J., Nowak, J. A., Rumble, R. B., Sargent, D. J., et al. (2017) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/s0ep-n080
The use of Peptide Microarrays in the study of O-GlcNAcylation, Phosphorylation and their Crosstalk
Sharif, S. (2023) · Utrecht University Repository (Utrecht University) · doi:10.33540/1663
Anticancer effects of mansonone G derivative on human colorectal cancer cells
Chanvijit, S. (2018) · Chula Digiverse · doi:10.58837/chula.the.2018.435
A Further Case for Targeting PRMT5 and the ERK1/2 and PI3K Pathways in CRC
Spivak, M., Pahmer, M., Delrahimnia, D., Sapir, T., & Shifteh, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110416
“The ERK1/2 and PI3K pathways are the chief signaling pathways for cellular proliferation, survival, and differentiation [5].”
Lam, R. C. T., Hui, C. W. C., Tse, I. O. L., Zhou, Q. X., Chow, C., Kang, W., Chan, K. C. A., Ma, B. B. Y., & Lam, W. K. (2025) · Case Reports in Oncological Medicine · doi:10.1155/crom/8140524 · Cited by 1
“However, our WES results revealed mutations in PI3K and WNT pathways that cross-talk with the MAPK pathway, which could account for our patient's resistance mechanism while on doublet and triplet therapy [18, 19].”
Additional file 1 of The safety and efficacy of binimetinib for lung cancer: a systematic review
Zahmatyar, M., Kharaz, L., Abiri Jahromi, N., Jahanian, A., Shokri, P., & Nejadghaderi, S. A. (2024) · Figshare · doi:10.6084/m9.figshare.26461750
Uncover the mechanism of action of new FeCp compounds in colorectal cancer cells
Silva, A. P. P. D. (2023) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/nvh9-6s02
Additional file 2 of The safety and efficacy of binimetinib for lung cancer: a systematic review
Zahmatyar, M., Kharaz, L., Abiri Jahromi, N., Jahanian, A., Shokri, P., & Nejadghaderi, S. A. (2024) · Figshare · doi:10.6084/m9.figshare.26461917
RHEBL1 expression is activated by the Oct4-Sox2 complex in oral squamous cell carcinoma
Qiu, F., Chen, Y., Li, P., Chen, Z., Lam, A. K.-Y., Liang, Y., Sun, X., Jiang, Q., & Qiao, B. (2026) · Functional & Integrative Genomics · doi:10.1007/s10142-026-01942-9
“These findings are consistent with previous reports on the role of RHEBL1 in other malignancies such as renal clear cell carcinoma and leukemia (Bailey et al. 2014 ; Temraz et al. 2015 ).”
Pankratova, E. D., Rubina, K. A., Kakotkin, V. V., Agapov, M. A., Сергеевна, К. П., Sysoeva, V., Kashchenko, A., & Semina, E. V. (2026) · medRxiv · doi:10.64898/2026.07.14.26357715
INVESTIGATING MONO-DRIVER VERSUS MULTI-DRIVER ONCOGENESIS VIA ALTERATIONS TO CELL SIGNALING PATHWAYS
Chapdelaine, A. G. (2025) · Digital Commons - URI (University of Rhode Island) · doi:10.23860/diss-4446
Analysis and Design of Frequency-Based Biological Signaling CascadesPreprint
Naeini, A. E., Nejad, S., O’Donnell, D., & Kuhlman, T. E. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.19.745833
Hamidi, A. A., Moaven, O., Mahmoudian, R. A., & Abbaszadegan, M. R. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00849-2
“Dual MAPK and PI3K-AKT inhibition is mechanistically compelling but has repeatedly encountered dermatologic, gastrointestinal and metabolic toxicity [105, 190–192].”
BindingDB (2020) · UC San Diego · doi:10.7270/q29w0j00
Metadata
- Authors
- Temraz, S., Mukherji, D., & Shamseddine, A.
- Affiliations
- American University of Beirut Medical Center (LB)
- Corresponding author
- Temraz, Sally
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2015-09-23
- Volume
- 16
- Issue
- 9
- Pages
- 22976-22988
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC4613347
- OpenAlex
- W2120687938
- Cited by
- 117
- References
- 55
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 12 · 2023: 9 · 2022: 2 · 2021: 9 · 2020: 13 · 2019: 15 · 2018: 19 · 2017: 16 · 2016: 10
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- colorectal cancer, MEK inhibitors, PI3K signaling, KRAS mutation, BRAF mutation, MAPK signaling, PI3K/mTOR inhibitors, drug resistance, Wnt signaling, PIK3CA, Akt, IGF-1 receptor, combination therapy
- MeSH terms
- Phosphoinositide-3 Kinase Inhibitors, Animals, Colon, Humans, Mutation, Rectum, Colorectal Neoplasms, Signal Transduction, Proto-Oncogene Proteins p21(ras), Mitogen-Activated Protein Kinase Kinases, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Phosphatidylinositol 3-Kinase, TOR Serine-Threonine Kinases, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.